Tarek Youssef Hosni, CEO of Jamjoom Pharma
He mentioned Tariq Youssef HosniCEO of the corporate Jamjoom PharmaThe corporate will proceed its path of development and attaining sustainable worth in the long run, indicating that it’s following its plan to realize a compound annual development charge in revenues between 12 and 15%, after recording annual development to this point of 13%. He added that the corporate raised the goal for the earnings margin earlier than curiosity, taxes, depreciation and amortization (EBITDA) to a stage ranging between 34 and 34.5%.
Hosni defined in an interview with: numbersThe corporate’s product line presently extends to 60 merchandise within the fields of ophthalmology, heart problems, dermatology, and client well being, together with 17 merchandise underneath evaluation by the Meals and Drug Administration, 22 merchandise prepared for submission, and 21 merchandise underneath improvement.
He identified that the corporate signed 13 strategic partnership agreements with worldwide firms to produce medicines within the Gulf markets and the Center East and North Africa area.
He said that the corporate continues to implement its sustainability agenda, which is predicated on enabling entry to healthcare at inexpensive costs, creating human competencies, sustainable manufacturing and operation, and governance and accountability, explaining that these elements, along with price effectivity, scalable operational capabilities, and rising worldwide partnerships, place the corporate in a powerful place to satisfy future healthcare wants and obtain long-term sustainable efficiency.
He confused the continuation of robust gross sales momentum in key markets throughout the first 9 months of 2025, which displays the power of operational execution and the corporate’s strategic focus.
He defined that the Saudi market was the first driver of development, as revenues elevated by 13.7% to succeed in 794.5 million riyals, equal to about two-thirds of whole revenues, supported by the rise in institutional gross sales quantity and the effectivity of provide chains.
He added that the Gulf area contributed 156.9 million riyals, with the UAE and Bahrain recording development of 18.8% and 20.9%, respectively, whereas the Iraqi market continued its constructive efficiency with a development of 15.7%, bringing revenues to 104.2 million riyals.
He said that Egypt recorded revenues value 59 million riyals, a rise of 14% in native forex, but it surely decreased by 4.3% in fixed worth on account of the decline within the alternate charge, whereas different export markets achieved 81.6 million riyals, a development of 11.1% on an annual foundation, supported by robust efficiency within the Francophone nations (French-speaking African nations) and Morocco.
He identified that the corporate’s income rose to 395.7 million riyals by the top of the primary 9 months of 2025, in comparison with 304.9 million riyals for a similar interval in 2024, whereas revenues grew by 13% to succeed in about 1.2 billion riyals.
He said that these outcomes replicate the continuation of the momentum achieved within the first half of the yr, and the power of the corporate’s enterprise mannequin to adapt to a dynamic working surroundings, supported by the strategic concentrate on therapeutic sectors with worth and excessive margin, improved working effectivity, and decrease financing prices, along with some non-recurring gadgets.
Hosni defined that the expansion in revenues throughout the interval was supported by robust efficiency within the primary therapeutic sectors, as basic medication recorded a exceptional development of 25.3%, whereas eye and dermatology merchandise contributed 522.6 million riyals, representing 43.7% of whole revenues. Gross sales of antidiabetics additionally elevated by 38.6%, the cardiovascular sector by 15%, whereas the digestive system sector recorded a development of 6.6%, the patron well being sector by 17.5%, the ache and irritation sector by 8.4%, and the central nervous system sector by 9.1%.
He added that the whole manufacturing throughout the corporate’s three factories reached 128 million models throughout the first 9 months of 2025, secure on an annual foundation with the redistribution of manufacturing capability throughout the technique of enhancing stock and specializing in high-value manufacturers. The manufacturing of the primary facility in Jeddah reached 100 million models with a utilization charge of 89.3%, the Egypt facility reached 22 million models with a utilization charge of 56.3%, and the brand new facility for sterile merchandise in Jeddah reached 6 million models with a utilization charge of 41.9%.
He confused that these numbers replicate the scalability of the manufacturing platform to satisfy the rising demand available in the market.
Relating to the Jamjoum Algeria venture, Hosni defined that the venture continues to make good progress and is a basic pillar of the corporate’s technique in North Africa, noting that the venture contributed 9.3 million riyals throughout the first 9 months of this yr to the monetary outcomes, with future plans to switch the manufacturing of the corporate’s main portfolio within the fields of eyes and dermatology to the native manufacturing facility after the completion of the capital funding.
Based on knowledge numbersrose earnings The corporate reached 395.7 million riyals by the top of the primary 9 months of 2025, by 30%, in comparison with income of 304.9 million riyals achieved throughout the identical interval in 2024.
